He began his pharmaceutical career with Reid-Provident Labs, a small entrepreneurial pharmaceutical company based in Atlanta, Ga. Mr. Schutter has a BS in Pharmacy from Mercer University and an MBA from Kennesaw State University. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. “Moreover, ArcherDX’s AMP technology enables decentralized testing, which we believe uniquely positions the Company to broadly impact the molecular cancer testing market.” Based on the quality and frequency of confirmatory data points, this metric represents the likelihood that a contact is employed where we say they are and that it is possible to reach them via email51 Astor Pl., 10th Fl.,
“Moreover, ArcherDX’s AMP technology enables decentralized testing, which we believe uniquely positions the Company to broadly impact the molecular cancer testing market.”
ARYA Sciences Acquisition II, the second healthcare-focused blank check company formed by Perceptive Advisors, filed on Tuesday with the SEC to raise up to $125 million in … With decades of experience at Johnson & Johnson and successful growth of two companies prior to Vitruvias, Bryce is a seasoned industry leader with an acute sense for business development and key partnerships.Michael Altman joined Perceptive in 2007 and is a senior analyst on the investment team. Michael graduated from the University of Vermont with a B.S. 51 Astor Pl., 10th Fl., Perceptive Advisors; 51 Astor Place, 10th floor New York, NY 10003 Phone: (646) 205-5300.
His leadership background coupled with a passion to expand the generic drug market have led to the development of multiple successful companies bringing next generation drugs into American pharmacies.Bryce Harvey leads Vitruvias as Vice Manager, Co-Founder and Director. Mr. Schutter also held several senior management roles in commercial operations at the U.S. subsidiary of Solvay during his twenty years with the organization. Michael Altman joined Perceptive in 2007 and is a senior analyst on the investment team.
Prior to joining Arbor, Mr. Schutter served as President and Chief Operating Officer of Sciele (Shionogi) Pharmaceuticals.
New York City, New York, 10003,
He joined Perceptive in 2007 from First New York Securit ... Apr 28, 2020
Mr. Schutter is currently President and Chief Executive Officer of Arbor Pharmaceuticals, a specialty pharmaceutical company focused on the cardiovascular, hospital, and pediatric markets as well as generics through its Wilshire division.
Michael Seth Altman’s peers at other companies are James Smith, Patrick McCarter, David Blume, Cy Cattan, Jason Gurandiano. Schutter is a seasoned executive with over 30 years of experience in the pharmaceutical industry.
Michael serves on the board of directors for Vensun Pharmaceuticals and Vitruvias Therapeutics.Mr. in Business Administration. We expect the Company's flagship products to enable tailored therapeutic selection for cancer patients by providing actionable insights," said Mike Altman, Managing Director, Perceptive … His focus is on medical devices, diagnostics,digital health and Specialty Pharmaceuticals. United StatesMichael Altman , CFA Managing Director Michael Altman , CFA Managing Director Michael Altman joined Perceptive in 2007 and is a managing direcMr.
He is also a member of the investment committee for the credit opportunities fund. We expect the Company’s flagship products to enable tailored therapeutic selection for cancer patients by providing actionable insights,” explained Perceptive Advisors managing director Mike Altman. United StatesFounded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. We expect the Company’s flagship products to enable tailored therapeutic selection for cancer patients by providing actionable insights,” said Mike Altman, Managing Director, Perceptive Advisors.